This piece is over Gilead pushing their injectable lencapavir from a twice a year subcutaneous injection to an annual intramuscular application. According to research, the results show a better concentration of the medicine than the current approach. The yearly shot had a higher dosage & injection site pain was common.
For those not interested or can't get the injections, Merck has developed another daily med with only 2 drugs. I don't know much on it so far, but I found this article.
We have an unexpected errand today. I hope things go well. I tried to do better yesterday. I didn't & spent most of the day on edge. Everything keeps piling on & I can't keep up or handle it. I'm not sure how things will go, but I am trying. It just doesn't seem to be enough.
That's all for now.
Cya...
No comments:
Post a Comment